The discovery of pyridone and pyridazone heterocycles as γ-secretase modulators

ACS Medicinal Chemistry Letters

Volumn 1, Issue 4, 2010, Pages 184-187

  Huang, Xianhai ^a   Aslanian, Robert ^a   Zhou, Wei ^a   Zhu, Xiaohong ^a   Qin, Jun ^a   Greenlee, William ^a   Zhu, Zhaoning ^a   Zhang, Lili ^a   Hyde, Lynn ^a   Chu, Inhou ^a   Cohen Williams, Mary ^a   Palani, Anandan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

secretase; Alzheimer's disease; modulator; Pyridazone; pyridine

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE INHIBITOR; HETEROCYCLIC COMPOUND; PYRIDAZINE DERIVATIVE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG CONFORMATION; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

RATTUS;

EID: 77955869481     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml1000799     Document Type: Article

References (15)

1. Gottwald, M. D.; Rozanski, R. I. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer?s disease: review and current status Expert Opin. Invest. Drugs 1999, 8, 1673 and references cited therein
2. Griffiths, H. H.; Morten, I.; Hooper, N. M. Emerging and potential therapies for Alzheimer?s disease Expert Opin. Ther. 2008, 12, 704
3. Williams, M. Progress in Alzheimer?s disease drug discovery: An update Curr. Opin. Invest. Drugs 2009, 10, 23
4. Pissarnitski, D. Advances in γ-secretase modulation Curr. Opin. Drug Discovery Dev. 2007, 10, 392
5. Shah, R. S.; Lee, H.-G.; Zhu, X.; Perry, G.; Smith, M. A.; Castellani, R. J. Current approaches in the treatment of Alzheimer?s disease Biomed. Pharmacother. 2008, 62, 199
6. Rajendran, L.; Schneider, A.; Schlechtingen, G.; Weidlich, S.; Ries, J.; Braxmeier, T.; Schwille, P.; Schulz, J. B.; Schroeder, C.; Simons, M.; Jennings, G.; Knoelker, H.-J.; Simons, K. Efficient inhibition of the Alzheimer?s disease β-secretase by membrane targeting Science 2008, 320 (5875) 520
7. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer?s disease: progress and problems on the road to therapeutics Science 2002, 297, 353 and references cited therein
8. Panza, F.; Solfrizzi, V.; Frisardi, V.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Vendemiale, G.; Capurso, A.; Imbimbo, B. P. Disease-modifying approach to the treatment of Alzheimer?s disease: From ?-secretase activators to γ-secretase inhibitors and modulators Drugs Aging 2009, 26, 537 and reference cited therein
9. Baumann, S.; Hoettecke, N.; Narlawar, R.; Schmidt, B. γ-Secretase as a target for AD Med. Chem. Alzheimer's Dis. 2008, 193 and reference cited therein
10. 1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H -dibenzo[ b, d ]azepin-7-yl]- L -alaninamide (LY411,575) in the CRND8 mouse J. Pharmacol. Exp. Ther. 2006, 319, 1133
11. Joo, Y.; Kim, H.-S.; Woo, R.-S.; Park, C. H.; Shin, K.-Y.; Lee, J.-P.; Chang, K.-A.; Kim, S.; Suh, Y.-H. Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer?s disease models Mol. Pharmacol. 2006, 69, 76
12. Davis, K. L. NSAID and Alzheimer?s disease; possible answers and new questions Mol. Psychiatry 2002, 7, 925
13. Korfmacher, W. A.; Cox, K. A.; Ng, K. J.; Veals, J.; Hsieh, Y.; Wainhaus, S.; Broske, L.; Prelusky, D.; Nomeir, A.; White, R. E. Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery Rapid Commun. Mass Spectrom. 2001, 15, 335
14. See the Supporting Information for the detailed assay procedure.
15. Kokotos, G.; Noula, C. Selective one-pot conversion of carboxylic acids into alcohols J. Org. Chem. 1996, 61, 6994